2-{4-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3,5-dimethylphenyl}-3-(4-sec-butylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one | 1235480-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-{4-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3,5-dimethylphenyl}-3-(4-sec-butylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one
• 英文别名: 2-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-3,5-dimethyl-phenyl}-3-(4-sec-butyl-phenyl)-3H-pyrido[4,3-d]pyrimidin-4-one；3-(4-butan-2-ylphenyl)-2-[4-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-3,5-dimethylphenyl]pyrido[4,3-d]pyrimidin-4-one
• CAS: 1235480-74-6
• 化学式: C₃₃H₄₃N₃O₃Si
• 分子量: 557.808
• InChiKey: VSEIDSXZPMUSSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.98
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-{4-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3,5-dimethylphenyl}-3-(4-sec-butylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 3-(4-sec-butylphenyl)-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)pyrido[4,3-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1

  摘要：

  An application claims non-naturally occurring upregulators of apolipoprotein A-1 (ApoA-1) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-1, and can potentially treat and prevent cardiovascular disease and related disease states, including cholesterol or lipid-related disorders, such as atherosclerosis. This application of Resverlogix Corp. increases the diversity of quinazolin-4 (3H)-ones capable of upregulating the expression of endogeneous ApoA-1.

  DOI：

  10.1517/13543776.2011.548322
• 作为产物：
  描述：

  4-羟基-3,5-二甲基苯甲酸 在 吡啶 、 4-二甲氨基吡啶 、 草酰氯 、 potassium carbonate 、 caesium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 吡啶 、 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-{4-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3,5-dimethylphenyl}-3-(4-sec-butylphenyl)-3H-pyrido[4,3-d]pyrimidin-4-one
  参考文献：
  名称：

  Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1

  摘要：

  An application claims non-naturally occurring upregulators of apolipoprotein A-1 (ApoA-1) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-1, and can potentially treat and prevent cardiovascular disease and related disease states, including cholesterol or lipid-related disorders, such as atherosclerosis. This application of Resverlogix Corp. increases the diversity of quinazolin-4 (3H)-ones capable of upregulating the expression of endogeneous ApoA-1.

  DOI：

  10.1517/13543776.2011.548322

文献信息

• COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：Hansen Henrik C.

  公开号：US20110294807A1

  公开（公告）日：2011-12-01

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

  本发明揭示了一种新型化合物，可用于调节载脂蛋白A-I（ApoA-I）的表达，并且其用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如动脉粥样硬化。还揭示了包含这种新型化合物的药物组合物。公式（I）
• Compounds for the prevention and treatment of cardiovascular disease
  申请人：Hansen Henrik C.

  公开号：US08952021B2

  公开（公告）日：2015-02-10

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

  本发明涉及新型化合物，其可用于调节载脂蛋白A-I（ApoA-I）的表达，并且可用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，如动脉粥样硬化。本发明还涉及包含这些新型化合物的药物组合物。公式（I）
• [EN] COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE<br/>[FR] COMPOSÉS POUR LA PRÉVENTION ET LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：RESVERLOGIX CORP

  公开号：WO2010079431A3

  公开（公告）日：2010-09-30
• Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1
  作者：Jianhui Wu、Ming Zhao、Shiqi Peng

  DOI：10.1517/13543776.2011.548322

  日期：2011.3

  An application claims non-naturally occurring upregulators of apolipoprotein A-1 (ApoA-1) quinazolin-4(3H)-ones. The claimed quinazolin-4(3H)-ones are efficacious in upregulating the expression of endogeneous ApoA-1, and can potentially treat and prevent cardiovascular disease and related disease states, including cholesterol or lipid-related disorders, such as atherosclerosis. This application of Resverlogix Corp. increases the diversity of quinazolin-4 (3H)-ones capable of upregulating the expression of endogeneous ApoA-1.